S-Ketamine's Effect Changes the Cortical Electrophysiological Activity Related to Semantic Affective Dimension of Pain: A Placebo- Controlled Study in Healthy Male Individuals.
ERPs
P300
ketamine
oddball
pain
Journal
Frontiers in neuroscience
ISSN: 1662-4548
Titre abrégé: Front Neurosci
Pays: Switzerland
ID NLM: 101478481
Informations de publication
Date de publication:
2019
2019
Historique:
received:
26
05
2019
accepted:
26
08
2019
entrez:
16
10
2019
pubmed:
16
10
2019
medline:
16
10
2019
Statut:
epublish
Résumé
Previous studies using the electroencephalogram (EEG) technique pointed out that ketamine decreases the amplitude of cortical electrophysiological signal during cognitive tasks, although its effects on the perception and emotional-valence judgment of stimuli are still unknown. We evaluated the effect of S-ketamine on affective dimension of pain using EEG and behavioral measures. The hypothesis was that S-ketamine would be more effective than placebo, both within and between groups, to attenuate the EEG signal elicited by target and non-target words. This double-blind parallel placebo-controlled study enrolled 24 healthy male volunteers between 19 and 40 years old. They were randomized to receive intravenous S-ketamine ( S-ketamine produced substantial difference (delta) in the AUC of grand average ERP components N200 ( Our findings suggest that S-ketamine actively changed the semantic processing of written words. There was an increase in electrophysiological response for pain-related stimuli and a decrease for standard stimuli, as evidenced by the increased delta of AUCs. Behaviorally, S-ketamine seems to have produced an emotional and discrimination blunting effect for pain-related words. www.ClinicalTrials.gov, identifier NCT03915938.
Sections du résumé
BACKGROUND
BACKGROUND
Previous studies using the electroencephalogram (EEG) technique pointed out that ketamine decreases the amplitude of cortical electrophysiological signal during cognitive tasks, although its effects on the perception and emotional-valence judgment of stimuli are still unknown.
OBJECTIVE
OBJECTIVE
We evaluated the effect of S-ketamine on affective dimension of pain using EEG and behavioral measures. The hypothesis was that S-ketamine would be more effective than placebo, both within and between groups, to attenuate the EEG signal elicited by target and non-target words.
METHODS
METHODS
This double-blind parallel placebo-controlled study enrolled 24 healthy male volunteers between 19 and 40 years old. They were randomized to receive intravenous S-ketamine (
RESULTS
RESULTS
S-ketamine produced substantial difference (delta) in the AUC of grand average ERP components N200 (
CONCLUSION
CONCLUSIONS
Our findings suggest that S-ketamine actively changed the semantic processing of written words. There was an increase in electrophysiological response for pain-related stimuli and a decrease for standard stimuli, as evidenced by the increased delta of AUCs. Behaviorally, S-ketamine seems to have produced an emotional and discrimination blunting effect for pain-related words.
CLINICAL TRIAL REGISTRATION
BACKGROUND
www.ClinicalTrials.gov, identifier NCT03915938.
Identifiants
pubmed: 31611759
doi: 10.3389/fnins.2019.00959
pmc: PMC6753200
doi:
Banques de données
ClinicalTrials.gov
['NCT03915938']
Types de publication
Journal Article
Langues
eng
Pagination
959Informations de copyright
Copyright © 2019 Schwertner, Zortea, Torres, Ramalho, Alves, Lannig, Torres, Fregni, Gauer and Caumo.
Références
Neuroimage. 2011 Sep 15;58(2):508-25
pubmed: 21723949
Anesthesiology. 2012 Oct;117(4):868-77
pubmed: 22890117
J Psychosom Res. 2010 Mar;68(3):223-33
pubmed: 20159207
Arch Gen Psychiatry. 2008 Feb;65(2):154-64
pubmed: 18250253
Psychopharmacology (Berl). 2003 Sep;169(3-4):215-33
pubmed: 12955285
Braz J Psychiatry. 2013 Oct-Dec;35(4):416-31
pubmed: 24402217
Biol Psychiatry Cogn Neurosci Neuroimaging. 2019 Feb;4(2):140-150
pubmed: 30115499
Front Psychol. 2016 Mar 02;7:271
pubmed: 26973569
Clin Neurophysiol. 2013 Mar;124(3):514-21
pubmed: 23063292
Anesthesiology. 2004 Feb;100(2):292-301
pubmed: 14739803
Arch Gen Psychiatry. 2006 Aug;63(8):856-64
pubmed: 16894061
J Biol Chem. 2009 Mar 6;284(10):6530-5
pubmed: 19116204
Anesthesiology. 2017 Apr;126(4):666-677
pubmed: 27984263
J Clin Psychiatry. 2017 Apr;78(4):e415-e419
pubmed: 28448702
CNS Drugs. 2012 Mar 1;26(3):189-204
pubmed: 22303887
Biol Psychiatry Cogn Neurosci Neuroimaging. 2017 Apr;2(3):253-262
pubmed: 29528296
Front Hum Neurosci. 2013 Sep 17;7:552
pubmed: 24062659
Anesthesiology. 2010 Sep;113(3):678-84
pubmed: 20693870
J Psychiatry Neurosci. 2017 Jun;42(4):222-229
pubmed: 28234212
Emotion. 2005 Mar;5(1):55-66
pubmed: 15755219
Synapse. 2008 Nov;62(11):819-28
pubmed: 18720422
J Exp Psychol Gen. 2001 Sep;130(3):466-78
pubmed: 11561921
Biol Psychiatry. 1998 Jun 1;43(11):811-6
pubmed: 9611670
J Clin Exp Neuropsychol. 2003 Sep;25(6):815-29
pubmed: 13680459
Neuropharmacology. 2003 May;44(6):729-37
pubmed: 12681371
J Exp Psychol Hum Percept Perform. 2016 Jun;42(6):878-889
pubmed: 26752733
Psychophysiology. 2003 Sep;40(5):684-701
pubmed: 14696723
Schizophr Res. 2016 Oct;176(2-3):83-94
pubmed: 27450778
Int J Neuropsychopharmacol. 2019 Feb 1;22(2):119-135
pubmed: 30445512
J Neurosci. 2009 Jan 21;29(3):600-9
pubmed: 19158287
Trends Cogn Sci. 2011 Nov;15(11):527-36
pubmed: 22001867
Anesth Prog. 1999 Winter;46(1):10-20
pubmed: 10551055
Int J Neuropsychopharmacol. 2009 Jul;12(6):823-32
pubmed: 19154656
Biol Psychiatry. 2012 Jun 1;71(11):969-77
pubmed: 22036036
Front Pharmacol. 2016 Sep 27;7:348
pubmed: 27729865
Neurosci Lett. 2000 Apr 21;284(1-2):53-6
pubmed: 10771160
Support Care Cancer. 2012 Feb;20(2):319-24
pubmed: 21243377
Soc Neurosci. 2014;9(4):364-77
pubmed: 24601745
Psychophysiology. 2001 Jul;38(4):607-21
pubmed: 11446574
Neuropsychopharmacology. 2001 Aug;25(2):165-72
pubmed: 11425500
Anesthesiology. 2009 Oct;111(4):892-903
pubmed: 19741495
Psychophysiology. 1993 May;30(3):261-73
pubmed: 8497555
J Neurochem. 2011 Oct;119(2):294-302
pubmed: 21692801
Biol Psychol. 2011 Sep;88(1):83-93
pubmed: 21742012
Int J Psychiatry Med. 1996;26(2):177-209
pubmed: 8877487
Int J Neuropsychopharmacol. 2009 Apr;12(3):357-70
pubmed: 18771605
Emotion. 2008 Dec;8(6):880-5
pubmed: 19102600
Neuroimage. 2016 Jan 1;124(Pt A):8-15
pubmed: 26348558
Anesth Analg. 2006 Sep;103(3):729-37
pubmed: 16931688
Rev Esc Enferm USP. 1996 Dec;30(3):473-83
pubmed: 9016160
Hum Brain Mapp. 2004 Aug;22(4):290-9
pubmed: 15202107
Mol Psychiatry. 2002;7(8):837-44
pubmed: 12232776
Biol Psychiatry. 2012 Jun 1;71(11):939-46
pubmed: 22297150
Arch Gen Psychiatry. 1994 Mar;51(3):199-214
pubmed: 8122957
Front Psychiatry. 2014 Jan 24;5:3
pubmed: 24478731
Psychophysiology. 2009 Jul;46(4):747-57
pubmed: 19386045
Electroencephalogr Clin Neurophysiol. 1983 Apr;55(4):468-84
pubmed: 6187540
Brain. 1998 Nov;121 ( Pt 11):2159-73
pubmed: 9827775
Percept Psychophys. 2000 Oct;62(7):1367-82
pubmed: 11143449
Expert Opin Pharmacother. 2010 Oct;11(14):2417-29
pubmed: 20828267
Cognition. 2008 Aug;108(2):557-65
pubmed: 18433742
Prog Neuropsychopharmacol Biol Psychiatry. 2003 Sep;27(6):993-9
pubmed: 14499316
Eur J Pain. 2018 Apr;22(4):632-646
pubmed: 29178663
Anesth Analg. 1966 Jan-Feb;45(1):29-40
pubmed: 5325977
Neurosci Lett. 2012 Apr 11;514(1):62-6
pubmed: 22395087